| Literature DB >> 23894584 |
Tamuno Alfred1, Yoav Ben-Shlomo, Rachel Cooper, Rebecca Hardy, Ian J Deary, Jane Elliott, Sarah E Harris, Mika Kivimaki, Meena Kumari, Chris Power, John M Starr, Diana Kuh, Ian N M Day.
Abstract
BACKGROUND: The glucokinase regulatory protein encoded by GCKR plays an important role in glucose metabolism and a single nucleotide polymorphism (SNP) rs1260326 (P446L) in the gene has been associated with several age-related biomarkers, including triglycerides, glucose, insulin and apolipoproteins. However, associations between SNPs in the gene and other ageing phenotypes such as cognitive and physical capability have not been reported.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23894584 PMCID: PMC3720952 DOI: 10.1371/journal.pone.0070045
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Summary of Sex, Age and GCKR Genotype Frequencies by Cohort.
| Cohort | Male (%) | Age | C/C | C/T | T/T | Total |
| median (range) | n (%) | n (%) | n (%) | |||
| NCDS | 50 | 44 | 1901 (36.4) | 2513 (48.1) | 808 (15.5) | 5222 |
| NSHD | 47 | 53 | 819 (35.8) | 1141 (49.8) | 329 (14.4) | 2289 |
| Whitehall II | 77 | 59 (50–73) | 1110 (35.3) | 1535 (48.8) | 502 (16.0) | 3147 |
| ELSA | 46 | 64 (52–90+) | 1922 (37.7) | 2438 (47.8) | 736 (14.4) | 5096 |
| LBC1921 | 42 | 79 (77–80) | 195 (39.2) | 230 (46.3) | 72 (14.5) | 497 |
| Total | 54 | 53 (44–90+) | 5947 (36.6) | 7857 (48.3) | 2447 (15.1) | 16251 |
Age at phase from which the majority of variables are taken, i.e. ELSA: II; LBC1921: I; NCDS: Biomedical Survey (2002); NSHD: 1999 Collection; Whitehall II: VII. ELSA: English Longitudinal Study of Ageing; NCDS: National Child Development Study; NSHD: National Survey of Health and Development.
rs780094 in ELSA, r2 = 0.93 with rs1260326.
Anthropometry and Biological Function by GCKR Genotype (Pooled Results).
| Model 1 | Model 2 | ||||||
| Variable | Total | Beta (95% CI) | p | I2%; Het p | Beta (95% CI) | p | I2%; Het p |
| Height, cm | 16251 | −0.011 (−0.030–0.007) | 0.23 | 24.6; 0.26 | 0.006 (−0.011–0.023) | 0.48 | 23.7; 0.26 |
| Weight, kg | 16251 | −0.018 (−0.047–0.011) | 0.23 | 45.1; 0.12 | −0.040 (−0.061–−0.020) | 0.0001 | 15.9; 0.31 |
| BMI, kg/m2 | 16251 | −0.011 (−0.041–0.019) | 0.48 | 37.1; 0.17 | −0.045 (−0.067–−0.022) | 0.0001 | 7.4; 0.36 |
| Waist-hip ratio | 15680 | 0.006 (−0.011–0.022) | 0.51 | 0.0; 0.51 | −0.010 (−0.024–0.004) | 0.15 | 0.0; 0.77 |
| Systolic blood pressure, mmHg | 15630 | 0.007 (−0.027–0.041) | 0.67 | 51.9; 0.08 | −0.002 (−0.035–0.032) | 0.92 | 52.8; 0.08 |
| Diastolic blood pressure, mmHg | 15630 | 0.003 (−0.035–0.042) | 0.87 | 61.3; 0.035 | −0.003 (−0.041–0.036) | 0.90 | 63.6; 0.027 |
| Pulse rate, BPM | 11990 | −0.003 (−0.028–0.022) | 0.80 | 0.0; 0.55 | −0.015 (−0.039–0.010) | 0.24 | 0.0; 0.42 |
| Forced vital capacity, L | 12587 | 0.013 (−0.006–0.032) | 0.19 | 0.0; 0.64 | 0.022 (0.005–0.039) | 0.013 | 0.0; 0.49 |
| Forced expiratory volume, L | 12588 | 0.019 (−0.012–0.051) | 0.23 | 51.5; 0.10 | 0.030 (−0.005–0.065) | 0.09 | 65.0; 0.036 |
| Fibrinogen, g/L | 13530 | 0.020 (−0.011–0.050) | 0.21 | 30.9; 0.23 | 0.019 (−0.008–0.046) | 0.16 | 15.7; 0.31 |
| Total cholesterol, mmol/L | 16251 | 0.052 (0.019–0.084) | 0.0018 | 47.6; 0.11 | 0.013 (−0.018–0.045) | 0.41 | 51.2; 0.08 |
| HDL cholesterol, mmol/L | 15575 | 0.000 (−0.037–0.037) | 0.98 | 64.3; 0.038 | 0.042 (0.003–0.081) | 0.033 | 75.0; 0.007 |
| Log triglycerides, mmol/L | 16251 | 0.105 (0.064–0.147) | 6.2×10−7 | 67.4; 0.015 | 0.112 (0.079–0.145) | 2.8×10−11 | 54.9; 0.064 |
| LDL cholesterol, mmol/L | 15128 | −0.004 (−0.027–0.019) | 0.75 | 0.0; 0.73 | −0.018 (−0.041–0.005) | 0.12 | 0.0; 0.90 |
| Glucose | 14106 | −0.042 (−0.066–−0.018) | 0.0007 | 0.0; 0.60 | −0.056 (−0.080–−0.033) | 2.6×10−6 | 0.0; 0.74 |
Het- heterogeneity. Beta coefficients per T allele based on z-scores.
Adjusted for age and sex.
Additional adjustments: i) height model: weight and triglycerides; ii) weight model: height and triglycerides; iii) triglycerides model: height and weight; iv) BMI model: triglycerides; v) all other models: height, weight and triglycerides.
Glucose in mmol/L or HbA1c in %.
Cognitive Capability by Cohort and GCKR Genotype.
| Model 1 | Model 2 | |||||||
| Variable | Cohort | Mean (SD) [n] | Beta (95% CI) | p | I2%; Het p | Beta (95% CI) | p | I2%; Het p |
| Word recall- 10 words | NCDS | 6.0 (1.5) [5159] | 0.00 (−0.04–0.04) | 0.85 | 0.01 (−0.03–0.04) | 0.79 | ||
| Word recall- 45 words | NSHD | 23.9 (6.3) [2235] | 0.05 (−0.01–0.12) | 0.08 | 0.07 (0.01–0.13) | 0.0324 | ||
| Word recall- 20 words | Whitehall II | 7.0 (2.4) [3103] | −0.03 (−0.08–0.02) | 0.25 | −0.02 (−0.07–0.02) | 0.33 | ||
| Word recall- 10 words | ELSA | 5.0 (1.7) [5044] | 0.02 (−0.02–0.06) | 0.31 | 0.03 (−0.01–0.06) | 0.16 | ||
|
|
|
|
|
|
|
|
| |
| Phonemic fluency- 1 letter | Whitehall II | 16.0 (4.1) [3093] | 0.03 (−0.02–0.08) | 0.20 | 0.04 (−0.01–0.09) | 0.11 | ||
| Phonemic fluency- 3 letters | LBC1921 | 40.5 (12.1) [494] | 0.01 (−0.12–0.14) | 0.84 | −0.00 (−0.13–0.13) | 0.99 | ||
|
|
|
|
|
|
|
|
| |
| Semantic fluency | NCDS | 22.5 (6.3) [5189] | −0.01 (−0.05–0.03) | 0.67 | −0.01 (−0.05–0.03) | 0.73 | ||
| NSHD | 23.7 (6.8) [2275] | 0.00 (−0.06–0.06) | 0.96 | 0.01 (−0.05–0.07) | 0.80 | |||
| Whitehall II | 16.0 (3.7) [3103] | 0.00 (−0.05–0.05) | 0.90 | 0.01 (−0.04–0.06) | 0.63 | |||
| ELSA | 20.3 (6.1) [5047] | 0.03 (−0.01–0.07) | 0.14 | 0.03 (−0.00–0.07) | 0.08 | |||
|
|
|
|
|
|
|
|
| |
| Search speed- 780 letters | NCDS | 333 (86) [5089] | 0.01 (−0.03–0.05) | 0.60 | 0.01 (−0.03–0.05) | 0.59 | ||
| Search speed- 600 letters | NSHD | 282 (76) [2264] | 0.00 (−0.06–0.06) | 0.95 | 0.01 (−0.05–0.07) | 0.73 | ||
| Search speed- 780 letters | ELSA | 300 (90) [4990] | 0.01 (−0.03–0.05) | 0.74 | 0.01 (−0.03–0.05) | 0.58 | ||
|
|
|
|
|
|
|
|
| |
Het- heterogeneity. Beta coefficients per T allele based on z-scores. NCDS: Sweep 8 (2008).
Adjusted for age and sex.
Additionally adjusted for height, weight and triglycerides in all models.
Full genotype model representing a significantly better fit than the given per allele model.
Physical Capability by Cohort and GCKR Genotype.
| Model 1 | Model 2 | |||||||
| Variable | Cohort | Mean (SD) [n] | Beta (95% CI) | p | I2%; Het p | Beta (95% CI) | p | I2%; Het p |
| Grip strength, kg | NSHD | 37.8 (14.4) [2206] | −0.01 (−0.05–0.04) | 0.77 | 0.00 (−0.04–0.05) | 0.84 | ||
| ELSA | 32.2 (11.5) [5053] | −0.00 (−0.03–0.02) | 0.86 | 0.00 (−0.02–0.03) | 0.82 | |||
| LBC1921 | 26.7 (9.1) [497] | −0.06 (−0.14–0.02) | 0.16 | −0.06 (−0.14–0.02) | 0.14 | |||
|
|
| − |
|
| − |
|
| |
| Timed 2.44 m walk, m/s | ELSA | 0.94 (0.29) [3222] | 0.03 (−0.01–0.08) | 0.17 | 0.05 (−0.00–0.09) | 0.05 | ||
| Timed 6 m walk, m/s | LBC1921 | 1.41 (0.37) [494] | 0.01 (−0.12–0.13) | 0.92 | −0.02 (−0.15–0.10) | 0.69 | ||
|
|
|
|
|
|
|
|
| |
| Timed chair rises | NSHD | 5.2 (1.7) [2148] | 0.01 (−0.05–0.08) | 0.69 | 0.01 (−0.05–0.07) | 0.76 | ||
| Timed chair rises | ELSA | 9.7 (3.1) [4472] | 0.02 (−0.02–0.06) | 0.24 | 0.03 (−0.01–0.07) | 0.17 | ||
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
| Balance <5s-One legged | NSHD | 87 (3.9) | 1.15 (0.84–1.58) | 0.37 | 1.18 (0.86–1.62) | 0.32 | ||
| Balance <5s-Tandem | ELSA | 573 (11.2) | 0.96 (0.84–1.10) | 0.58 | 0.94 (0.81–1.08) | 0.35 | ||
|
|
|
|
|
|
|
|
| |
Het- heterogeneity. Beta coefficients per T allele based on z-scores.
Adjusted for age and sex.
Additionally adjusted for height, weight and triglycerides in all models.
Reciprocal of time taken in sec × 100.
Data within cohorts represent the number (%) of participants unable to balance for at least 5s. Data for pooled row represent the number of participants unable to balance for at least 5s/number of participants who performed the test.